Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
It’s one thing to appreciate how Guardian Pharmacy Services, Inc. keeps assisted-living residents adherent to medication; it’s another to untangle the reimbursement footnotes, controlled-substance disclosures, and state-by-state regulations buried in SEC reports. Investors routinely spend hours locating pharmacy automation costs or Medicaid mix details, which is why searches like “Guardian Pharmacy Services insider trading Form 4 transactions” or “how to read the company’s 10-K” are so common.
Stock Titan’s AI solves that complexity. Our platform delivers Guardian Pharmacy Services quarterly earnings report 10-Q filing highlights, with segment revenue and technology spend distilled into plain language. Need governance data? The Guardian Pharmacy Services proxy statement executive compensation tables are cross-referenced against prior years. Real-time alerts surface Guardian Pharmacy Services Form 4 insider transactions real-time, so you never miss executive stock transactions Form 4. Sudden news is covered through Guardian Pharmacy Services 8-K material events explained, while bigger-picture trends appear in the Guardian Pharmacy Services annual report 10-K simplified. Every document streams from EDGAR the moment it’s posted, complete with AI-powered summaries that make Guardian Pharmacy Services SEC filings explained simply.
Whether you’re tracking margin pressures, comparing quarter-over-quarter adherence metrics, or timing trades around board activity, understanding Guardian Pharmacy Services SEC documents with AI saves hours. Dive into Guardian Pharmacy Services earnings report filing analysis, export numbers directly to your model, or monitor compliance flags—all in one place. From insider activity to cash-flow shifts, our comprehensive coverage equips professionals to act decisively.
Gilead Sciences (GILD) – Form 4 insider transaction: Chairman & CEO Daniel P. O’Day sold a total of 10,000 common shares on 28 Jul 2025 under a Rule 10b5-1 trading plan adopted 28 Feb 2025.
- Sales executed in two blocks: 1,655 sh @ $113.17 avg and 8,345 sh @ $114.09 avg, implying total proceeds of roughly $1.13 million.
- Post-sale direct ownership falls to 605,725 shares, down ~1.6 % from 615,725 pre-trade.
- No derivative transactions were reported.
The modest size and pre-planned nature of the sale suggest limited informational value, but investors often monitor CEO transactions for sentiment cues.
On 06/30/2025 The Vanguard Group filed Amendment No. 1 to Schedule 13G covering Guardian Pharmacy Services Inc. (GRDN). Vanguard reports beneficial ownership of 966,806 common shares (CUSIP 40145W101), equal to 4.25 % of the outstanding stock. The investment adviser holds 0 shares with sole voting power and 16,335 shares with shared voting power; it retains 934,250 shares with sole dispositive power and 32,556 shares with shared dispositive power. Vanguard certifies the stake is held in the ordinary course of business with no intent to influence control. Item 5 notes that ownership is now below the 5 % reporting threshold.
FAQ
What is the current stock price of Guardian Pharmacy Services (GRDN)?
What is the market cap of Guardian Pharmacy Services (GRDN)?
What primary services does Guardian Pharmacy Services, Inc. offer?
How does Guardian Pharmacy Services integrate technology in its operations?
Which segments of the healthcare market does the company primarily serve?
What are some key operational strengths of Guardian Pharmacy Services?
How does the company improve clinical outcomes in the facilities it serves?
What differentiates Guardian Pharmacy Services from other pharmacy service providers?
How does the company support cost efficiency in care facilities?
What role does clinical oversight play in the company’s service delivery?
